Pharmacokinetic Interactions between Primaquine and Pyronaridine-Artesunate in Healthy Adult Thai Subjects
Open Access
- 1 January 2015
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 59 (1), 505-513
- https://doi.org/10.1128/aac.03829-14
Abstract
Pyronaridine-artesunate is a newly introduced artemisinin-based combination treatment which may be deployed together with primaquine. A single-dose, randomized, three-sequence crossover study was conducted in healthy Thai volunteers to characterize potential pharmacokinetic interactions between these drugs. Seventeen healthy adults received a single oral dose of primaquine alone (30 mg base) and were then randomized to receive pyronaridine-artesunate alone (540−180 mg) or pyronaridine-artesunate plus primaquine in combination, with intervening washout periods between all treatments. The pharmacokinetic properties of primaquine, its metabolite carboxyprimaquine, artesunate, its metabolite dihydroartemisinin, and pyronaridine were assessed in 15 subjects using a noncompartmental approach followed by a bioequivalence evaluation. All drugs were well tolerated. The single oral dose of primaquine did not result in any clinically relevant pharmacokinetic alterations to pyronaridine, artesunate, or dihydroartemisinin exposures. There were significantly higher primaquine maximum plasma drug concentrations (geometric mean ratio, 30%; 90% confidence interval [CI], 17% to 46%) and total exposures (15%; 6.4% to 24%) during coadministration with pyronaridine-artesunate than when primaquine was given alone. Pyronaridine, like chloroquine and piperaquine, increases plasma primaquine concentrations. (This study has been registered at ClinicalTrials.gov under registration no. NCT01552330.)Keywords
This publication has 35 references indexed in Scilit:
- The metabolism of primaquine to its active metabolite is dependent on CYP 2D6Malaria Journal, 2013
- Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trialsMalaria Journal, 2013
- Primaquine for reducingPlasmodium falciparumtransmissionPublished by Wiley ,2012
- Review of pyronaridine anti-malarial properties and product characteristicsMalaria Journal, 2012
- CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquineMalaria Journal, 2012
- Drug-Drug Interaction Analysis of Pyronaridine/Artesunate and Ritonavir in Healthy VolunteersThe American Journal of Tropical Medicine and Hygiene, 2012
- Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administrationMalaria Journal, 2011
- A review of mixed malaria species infections in anopheline mosquitoesMalaria Journal, 2011
- Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteersEuropean Journal of Clinical Pharmacology, 2009
- Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects?British Journal of Clinical Pharmacology, 2006